Skip to content

US · STAA · MEDICAL - INSTRUMENTS & SUPPLIES

STAAR Surgical Company (STAA) intrinsic value and stock valuation

$24.22as of 2026-11-21 · Mkt cap 1.14B

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

STAAR Surgical Company DCF and intrinsic value

InvestorsCraft values STAA with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from STAA’s statements →

STAAR Surgical Company Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Instruments & Supplies Lake Forest, CA 92630 staar.com

How the business is doing

Fiscal 2009–2026, USD

Revenue
$239.4M+9.8% 5y CAGRd
20092026
Net income
-$-80.45M
20092026
Free cash flow
-$-40.05M
20092026
Total equity
$344.2M+16.6% 5y CAGRd
20092026

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2009–2026, USD
20262024202320222021
Revenue$239.4M$313.9M$322.4M$284.4M$230.5M
Operating income-$-45.95M-$-12.61M$28.1M$43.8M$33.3M
Net income-$-80.45M-$-20.21M$21.4M$39.7M$27.5M
EPSd-$-1.62M-$-411.44K$431.9K$803.2K$556.2K
Operating cash flow-$-34.23M$15.7M$14.6M$35.7M$44M
Capital expenditure-$-5.82M-$-23.39M-$-18.19M-$-18.11M-$-13.64M
Free cash flow-$-40.05M-$-7.67M-$-3.59M$17.6M$30.3M
Total assets$461.6M$509.5M$488.7M$418.8M$345.8M
Total debt$38.4M$38.7M$35.8M$31M$32.1M
Net debt-$-114.8M-$-105.42M-$-147.2M-$-55.44M-$-167.65M
Total equity$344.2M$397.3M$386M$336.1M$258.6M
Cash and short-term investments$187.5M$230.5M$220.7M$211.6M$199.7M
Income statement
20262024202320222021
Revenue$239.4M$313.9M$322.4M$284.4M$230.5M
Cost of revenue$57M$74.3M$69.8M$61M$51.8M
Gross profit$182.4M$239.6M$252.7M$223.4M$178.6M
Research and development expenses$40.1M$54M$44.4M$36M$33.9M
Selling, general and administrative expenses$188.3M$198.2M$180.2M$143.6M$111.4M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$228.4M$252.2M$224.6M$179.6M$145.3M
Cost and expenses$285.4M$326.5M$294.3M$240.6M$197.1M
Interest income$4.59M$5.91M$6.99M$2.45M$0.00
Interest expense$0.00$0.00$0.00$0.00$40K
Depreciation and amortization$8.73M$6.89M$5.12M$4.51M$3.64M
Ebitda-$-73.53M-$-2.16M$38.8M$50.1M$35M
Operating income-$-45.95M-$-12.61M$28.1M$43.8M$33.3M
Total other income/expenses, net-$-36.32M$3.56M$5.6M$1.75M-$-2.04M
Income before tax-$-82.26M-$-9.05M$33.7M$45.6M$31.3M
Income tax expense-$-1.81M$11.2M$12.4M$5.89M$3.79M
Net income-$-80.45M-$-20.21M$21.4M$39.7M$27.5M
Weighted average shares outstanding$49.6M$49.1M$48.5M$48M$47.2M
Weighted average diluted shares outstanding$49.6M$49.1M$49.4M$49.4M$49.5M
Balance sheet
20262024202320222021
Cash and short-term investments$187.5M$230.5M$220.7M$211.6M$199.7M
Net receivables$54.6M$79.3M$98M$66M$46.6M
Inventory$55.5M$43.3M$35.1M$24.2M$17.3M
Total current assets$311.6M$367.9M$365.3M$311.7M$271.4M
Property, plant and equipment, net$102.9M$121.8M$101.4M$81.5M$67.7M
Goodwill and intangible assets$32.5M$1.79M$1.79M$1.96M$2M
Long-term investments$0.00$0.00$11.7M$13.9M$0.00
Total non-current assets$150.1M$141.6M$123.4M$107.1M$74.4M
Total assets$461.6M$509.5M$488.7M$418.8M$345.8M
Accounts payable$11.6M$16.7M$13.6M$11.6M$8.7M
Short-term debt$5.87M$3.94M$4.37M$3.69M$3.41M
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$68.5M$70.3M$65M$51.7M$48.8M
Long-term debt$32.5M$34.8M$31.5M$27.4M$28.7M
Deferred revenue, non-current$90K$0.00$0.00$0.00$0.00
Total non-current liabilities$48.9M$41.9M$37.7M$31M$38.4M
Capital lease obligations$38.4M$38.7M$35.8M$31M$32.1M
Total liabilities$117.4M$112.2M$102.7M$82.7M$87.2M
Common stock$500K$490K$490K$480K$480K
Retained earnings-$-148.02M-$-67.58M-$-47.37M-$-68.72M-$-111.39M
Accumulated other comprehensive income (loss)-$-6.51M-$-7.03M-$-4.11M$160K-$-4.05M
Total equity$344.2M$397.3M$386M$336.1M$258.6M
Total investments$34.4M$86.3M$49.4M$139.1M$0.00
Total debt$38.4M$38.7M$35.8M$31M$32.1M
Net debt-$-114.8M-$-105.42M-$-147.2M-$-55.44M-$-167.65M
Cash flow statement
20262024202320222021
Net income-$-80.45M-$-20.21M$21.4M$39M$27.5M
Depreciation and amortization$8.32M$6.89M$5.12M$4.51M$3.64M
Stock-based compensation$30.6M$27.2M$23.5M$20.4M$14.6M
Change in working capital-$-16.33M-$-5.4M-$-40.84M-$-29.13M-$-2.39M
Accounts receivable$27.8M$20K-$-32.76M-$-19.6M-$-8.87M
Inventory-$-16.98M-$-10K-$-14.36M-$-7.94M$70K
Accounts payable-$-5.51M$0.00-$-700K$1.8M$110K
Net cash provided by operating activities-$-34.23M$15.7M$14.6M$35.7M$44M
Investments in property, plant and equipment-$-5.82M-$-23.39M-$-18.19M-$-18.11M-$-13.64M
Acquisitions, net$0.00$0.00$0.00$138.3M$0.00
Net cash used for investing activities$46.3M-$-59.22M$74.4M-$-156.38M-$-13.64M
Common stock issued$3.47M$0.00$0.00$0.00$0.00
Common stock repurchased-$-6.46M-$-1.5M-$-2.1M$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-4.55M$5.72M$7.42M$8.3M$17.8M
Net change in cash$8.99M-$-38.88M$96.6M-$-113.23M$47.3M
Cash at end of period$153.2M$144.2M$183M$86.5M$199.7M
Operating cash flow-$-34.23M$15.7M$14.6M$35.7M$44M
Capital expenditure-$-5.82M-$-23.39M-$-18.19M-$-18.11M-$-13.64M
Free cash flow-$-40.05M-$-7.67M-$-3.59M$17.6M$30.3M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About STAAR Surgical Company

        STAAR Surgical Company, along with its subsidiaries, specializes in ophthalmological solutions, focusing on the design, development, manufacturing, and commercialization of implantable lenses for vision correction, complete with the sophisticated delivery systems necessary for their implantation. A core offering is the Visian implantable Collamer lens (ICL) product line, designed to correct various visual impairments including myopia (nearsightedness), hyperopia (farsightedness), astigmatism, and presbyopia (age-related loss of near vision). Specifically, their Hyperopic ICL addresses farsightedness. Furthermore, STAAR Surgical provides preloaded silicone intraocular lenses and associated injector systems, crucial for cataract surgery. The company also sells various injector components and ancillary medical instruments and devices. Its market outreach extends to a diverse array of healthcare providers, such as ophthalmic surgeons, specialized vision and surgical centers, hospitals, governmental healthcare facilities, and distributors. These products are predominantly utilized by ophthalmologists. Sales are conducted directly via its own sales force in key countries like the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore. In other significant markets, including China, Korea, India, France, the Benelux region, Italy, and other international territories, the company employs a hybrid sales model, leveraging both its direct representatives and independent distributors. Founded in 1982, STAAR Surgical Company is headquartered in Lake Forest, California.

        CEO
        Deborah J. Andrews
        Employees
        1.16K
        Beta
        1.23

        Explore

        Frequently asked questions

        What is the intrinsic value of STAAR Surgical Company (STAA)?

        InvestorsCraft does not currently publish an intrinsic value for STAA. How the IC value is calculated.

        Is STAA undervalued?

        InvestorsCraft does not publish an undervaluation signal for STAA at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.